Literature DB >> 33456987

Qingjie Fuzheng Granules regulates cancer cell proliferation, apoptosis and tumor angiogenesis in colorectal cancer xenograft mice via Sonic Hedgehog pathway.

Xiao-Qin Zhu1,2, Hong Yang1,2, Ming-He Lin3, Hai-Xia Shang1,2, Jun Peng1,2, Wu-Jin Chen4, Xu-Zheng Chen1,2, Jiu-Mao Lin1,2.   

Abstract

BACKGROUND: Sonic Hedgehog (SHh) signaling pathway plays a critical role in cell proliferation, apoptosis, and tumor angiogenesis in various types of malignancies including colorectal cancer (CRC). Qingjie Fuzheng Granules (QFG) is a traditional Chinese medicinal formula, which has been clinically used in various cancer treatments, including CRC. In this study, we explored the potential molecular mechanisms of QFG treatment effects on CRC via the SHh pathway.
METHODS: A CRC HCT-116 xenograft mouse model was utilized for all experiments. Mice were treated with intra-gastric administration of 1 g/kg of QFG or saline 6 days a week for 28 days (4 weeks). Body weight, length and shortest diameter of the tumor were measured every 3 days. At the end of the treatment, the tumor weight was measured. TUNEL staining assays were used to detect tumor apoptosis. Western blot and immunohistochemistry (IHC) assays were used to detect the expression of relative proteins.
RESULTS: In our results, QFG inhibited the increase of tumor volume and weight, and exhibited no impact on mouse body weight. Furthermore, QFG significantly decreased the expression of SHh, Smo and Gli proteins, indicating the action of SHh signaling. Consequently, the expression of pro-proliferative survivin, Ki-67, Cyclin-D1 and CDK4 were decreased and expression of anti-proliferative p21 was increased. The pro-apoptotic Bax/Bcl-2 ratio, cle-caspase-3 and TUNEL-positive cell percentage in tumor tissues were increased. Meanwhile, the pro-angiogenic VEGF-A and VEGFR-2 expression was down-regulated.
CONCLUSIONS: QFG inhibited CRC cell proliferation and promoted CRC cell apoptosis and tumor angiogenesis in vivo through the suppression of SHh pathway, suggesting that QFG could be a potential therapeutic drug for CRC. 2020 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Qingjie Fuzheng Granules (QFG); angiogenesis; apoptosis; colorectal cancer (CRC); proliferation

Year:  2020        PMID: 33456987      PMCID: PMC7807284          DOI: 10.21037/jgo-20-213

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  46 in total

1.  Analysis of Bcl-2, Bax and Survivin genes in uterine cancer.

Authors:  Y Saitoh; Y Yaginuma; M Ishikawa
Journal:  Int J Oncol       Date:  1999-07       Impact factor: 5.650

2.  Implications of cleaved caspase 3 and AIF expression in colorectal cancer based on patient age.

Authors:  Aurélie Perraud; Hussein Akil; Michelle Nouaille; Daniel Petit; François Labrousse; Marie-Odile Jauberteau; Muriel Mathonnet
Journal:  Oncol Rep       Date:  2012-03-20       Impact factor: 3.906

3.  Survivin promotes cell proliferation in human hepatocellular carcinoma.

Authors:  T Ito; K Shiraki; K Sugimoto; T Yamanaka; K Fujikawa; M Ito; K Takase; M Moriyama; H Kawano; M Hayashida; T Nakano; A Suzuki
Journal:  Hepatology       Date:  2000-05       Impact factor: 17.425

4.  Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.

Authors:  Rodrigo Panno Basilio-de-Oliveira; Vera Lucia Nunes Pannain
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

5.  Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest.

Authors:  Xiang Ling; Ralph J Bernacki; Michael G Brattain; Fengzhi Li
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

6.  Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer?

Authors:  Ehsan Khodapasand; Narges Jafarzadeh; Farid Farrokhi; Behnam Kamalidehghan; Massoud Houshmand
Journal:  Iran Biomed J       Date:  2015

7.  The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells.

Authors:  Denis V Baev; Janusz Krawczyk; Michael O׳Dwyer; Eva Szegezdi
Journal:  Leuk Res Rep       Date:  2014-09-01

8.  Genipin suppresses colorectal cancer cells by inhibiting the Sonic Hedgehog pathway.

Authors:  Bo Ram Kim; Yoon A Jeong; Yoo Jin Na; Seong Hye Park; Min Jee Jo; Jung Lim Kim; Soyeon Jeong; Suk-Young Lee; Hong Jun Kim; Sang Cheul Oh; Dae-Hee Lee
Journal:  Oncotarget       Date:  2017-10-16

9.  Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer.

Authors:  C Sarasqueta; A Perales; A Escobar; M Baré; M Redondo; N Fernández de Larrea; E Briones; J M Piera; M V Zunzunegui; J M Quintana
Journal:  BMC Cancer       Date:  2019-07-25       Impact factor: 4.430

Review 10.  Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.

Authors:  Chloe J Peach; Viviane W Mignone; Maria Augusta Arruda; Diana C Alcobia; Stephen J Hill; Laura E Kilpatrick; Jeanette Woolard
Journal:  Int J Mol Sci       Date:  2018-04-23       Impact factor: 5.923

View more
  3 in total

1.  Disordered Gut Microbiota in Colorectal Tumor-Bearing Mice Altered Serum Metabolome Related to Fufangchangtai.

Authors:  Mengmeng Cai; Ya Xiao; Zhibing Lin; Jinmiao Lu; Xiaoyu Wang; Sajid Ur Rahman; Shilan Zhu; Xiaoyu Chen; Jialin Gu; Yuzhu Ma; Zhaoguo Chen; Jiege Huo
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

2.  Based on the Network Pharmacology to Investigate the Mechanism of Qingjie Fuzheng Granules against Colorectal Cancer.

Authors:  Yi Fang; Chi Yang; Yao Lu; Lihui Wei; Jinyan Zhao; Lisha Lu; Jiumao Lin
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-04       Impact factor: 2.629

3.  Asiaticoside reverses M2 phenotype macrophage polarization-evoked osteosarcoma cell malignant behaviour by TRAF6/NF-κB inhibition.

Authors:  Dang-Ke Li; Guang-Hui Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.